{"id":533662,"date":"2021-09-02T07:04:23","date_gmt":"2021-09-02T11:04:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/"},"modified":"2021-09-02T07:04:23","modified_gmt":"2021-09-02T11:04:23","slug":"zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/","title":{"rendered":"Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">DEVON, Pa., Sept.  02, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=crVf-ctjPUk4fYbwJO10fJzl7XRxCukw89hHBV8CTUvwPeeNg42rWDN_rVMyQgwV4INTXnYNWd7pLJG0OWCQpoJER5BmZcW47xjZa0Es6V4=\" rel=\"nofollow noopener\" target=\"_blank\">Zynerba Pharmaceuticals<\/a>, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021, which will be held virtually from September 9-10, 2021. A copy of the presentation slides will be made available on the Zynerba corporate website following each presentation at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yS96jqEjBlOXg9tb6aY2Q_nXP-h5CAFlgZZ1QoyX9UlgWhhhvx77Rlcox-bLoVSmkh63yVrPwh5xmyr6oHkt3PvYQ3IiiB8rJMcOpwaVTm-QsyeE0Us5AEPqox8lhPAl\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/zynerba.com\/publications\/<\/a>. Additional meeting information can be found on the SSBP website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4Oounv_q4ROFYSmeadBkOuD6Fco-WKy3Yf3CAuaBdhapwYJJM0JCyo6tmbsvEYy7ebOxWA63OhMCkRQQ7LXlnw==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ssbp.org.uk\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Oral Presentation Details<\/u><br \/>\n        <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:11%;width:11%;min-width:11%\">Title:<\/td>\n<td style=\"max-width:89%;width:89%;min-width:89%\">Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study (BRIGHT [ZYN2-CL-030])<\/td>\n<\/tr>\n<tr>\n<td>Session:<\/td>\n<td>Session 1<\/td>\n<\/tr>\n<tr>\n<td>Date:<\/td>\n<td>September 9, 2021<\/td>\n<\/tr>\n<tr>\n<td>Time:<\/td>\n<td>5:15 a.m. ET<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Title:<\/td>\n<td>A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]<\/td>\n<\/tr>\n<tr>\n<td>Session:<\/td>\n<td>Session 4<\/td>\n<\/tr>\n<tr>\n<td>Date:<\/td>\n<td>September 10, 2021<\/td>\n<\/tr>\n<tr>\n<td>Time:<\/td>\n<td>2:15 p.m. ET<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>About Zynerba Pharmaceuticals, Inc.<\/strong><br \/>\n        \n      <\/p>\n<p align=\"justify\">Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c2F3BIinKxLJbAojt0NSTaj1sVlSoRlTD57IRBqVECZtiZdFUS0x8m3CRiJMfEcciV2vuRWndrKiUOueMPOUMA==\" rel=\"nofollow noopener\" target=\"_blank\">www.zynerba.com<\/a> and follow us on Twitter at @ZynerbaPharma.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Note on Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company\u2019s current expectations. Management\u2019s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the Company\u2019s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company\u2019s expectations, projections and estimates regarding expenses, future revenue, capital requirements, incentive and other tax credit eligibility, collectability and timing, and availability of and the need for additional financing; the Company\u2019s ability to obtain additional funding to support its clinical development programs; the results, cost and timing of the Company\u2019s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; clinical results for the Company\u2019s product candidates may not be replicated or continue to occur in additional trials and may not otherwise support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration and foreign regulatory agencies may affect the design, initiation, timing, continuation and\/or progress of clinical trials or result in the need for additional clinical trials; the Company\u2019s ability to obtain and maintain regulatory approval for its product candidates, and the labeling under any such approval; the Company\u2019s reliance on third parties to assist in conducting pre-clinical and clinical trials for its product candidates; delays, interruptions or failures in the manufacture and supply of the Company\u2019s product candidates the Company\u2019s ability to commercialize its product candidates; the size and growth potential of the markets for the Company\u2019s product candidates, and the Company\u2019s ability to service those markets; the Company\u2019s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company\u2019s product candidates; the Company\u2019s expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates; the timing and outcome of current and future legal proceedings; and the extent to which health epidemics and other outbreaks of communicable diseases, including COVID-19, could disrupt our operations or adversely affect our business and financial conditions. This list is not exhaustive and these and other risks are described in the Company\u2019s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at\u00a0www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p>\n        <strong>Zynerba Contacts<\/strong>\n      <\/p>\n<p>Peter Vozzo<br \/>Westwicke\/ICR<br \/>Office: 443.213.0505<br \/>Cell: 443.377.4767<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qyYKuYPjDAPe95CExJP4ZoO4AnKpRZHlRZ7M_FqNEYj9jdBPOPYIrrilnis8VLysA9MkNt6x-ypLYPQqceUsJMXnHwMzwG2MMwCp3T6QgrU=\" rel=\"nofollow noopener\" target=\"_blank\">Peter.Vozzo@Westwicke.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE5OSM0Mzg1ODkwIzIwMTcyOTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTViODU4YjktMmQ2Ny00YWUyLTg0OTktZWI1NTQ1YTgxMjgzLTEwMjg4Njg=\/tiny\/Zynerba-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021, which will be held virtually from September 9-10, 2021. A copy of the presentation slides will be made available on the Zynerba corporate website following each presentation at http:\/\/zynerba.com\/publications\/. Additional meeting information can be found on the SSBP website at\u00a0https:\/\/ssbp.org.uk\/. Oral Presentation Details Title: Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-533662","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021, which will be held virtually from September 9-10, 2021. A copy of the presentation slides will be made available on the Zynerba corporate website following each presentation at http:\/\/zynerba.com\/publications\/. Additional meeting information can be found on the SSBP website at\u00a0https:\/\/ssbp.org.uk\/. Oral Presentation Details Title: Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study &hellip; Continue reading &quot;Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T11:04:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE5OSM0Mzg1ODkwIzIwMTcyOTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021\",\"datePublished\":\"2021-09-02T11:04:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/\"},\"wordCount\":819,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTE5OSM0Mzg1ODkwIzIwMTcyOTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/\",\"name\":\"Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTE5OSM0Mzg1ODkwIzIwMTcyOTU=\",\"datePublished\":\"2021-09-02T11:04:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTE5OSM0Mzg1ODkwIzIwMTcyOTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTE5OSM0Mzg1ODkwIzIwMTcyOTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/","og_locale":"en_US","og_type":"article","og_title":"Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 - Market Newsdesk","og_description":"DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021, which will be held virtually from September 9-10, 2021. A copy of the presentation slides will be made available on the Zynerba corporate website following each presentation at http:\/\/zynerba.com\/publications\/. Additional meeting information can be found on the SSBP website at\u00a0https:\/\/ssbp.org.uk\/. Oral Presentation Details Title: Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study &hellip; Continue reading \"Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T11:04:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE5OSM0Mzg1ODkwIzIwMTcyOTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021","datePublished":"2021-09-02T11:04:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/"},"wordCount":819,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE5OSM0Mzg1ODkwIzIwMTcyOTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/","name":"Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE5OSM0Mzg1ODkwIzIwMTcyOTU=","datePublished":"2021-09-02T11:04:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE5OSM0Mzg1ODkwIzIwMTcyOTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTE5OSM0Mzg1ODkwIzIwMTcyOTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zynerba-pharmaceuticals-announces-oral-presentations-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-conference-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=533662"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533662\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=533662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=533662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=533662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}